What is Engeneic?
EnGeneIC specializes in the research, development, and manufacturing of targeted anti-cancer therapies, anchored by its innovative EDV nanocell platform. This first-in-class cyto-immunotherapy technology is designed to directly target tumor cells while simultaneously activating the patient's immune system to combat malignancy. Unlike traditional chemotherapy, which often results in systemic toxicity, the EDV platform offers a highly specific delivery mechanism. Currently, the company is advancing its clinical agenda with Phase I/IIa trials, specifically evaluating EGFR-targeted EDV nanocells in patients suffering from advanced solid tumors. This focus on high-precision oncology places EnGeneIC at the forefront of the biopharmaceutical industry, bridging the gap between laboratory innovation and clinical application.
How much funding has Engeneic raised?
Engeneic has raised a total of $18M across 3 funding rounds:
Private Equity
$1M
Series A
$7M
Series B
$10M
Private Equity (2011): $1M, investors not publicly disclosed
Series A (2014): $7M, investors not publicly disclosed
Series B (2014): $10M supported by Foley Ventures and GRT Capital Partners LLC
Key Investors in Engeneic
Foley Ventures
Foley Ventures is an independent venture capital firm that invests across diverse sectors including biotechnology and healthcare, providing strategic support to foster innovation.
GRT Capital Partners LLC
GRT Capital Partners LLC is a private investment firm focused on identifying and supporting high-growth companies with significant market potential.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Engeneic?
With the recent capital injection, EnGeneIC is poised to scale its clinical trial operations and refine its manufacturing capabilities for the EDV nanocell platform. The strategic focus remains on demonstrating the safety and efficacy of its lead candidates in human trials, a critical step toward regulatory approval and eventual commercialization. As the company navigates the complexities of late-stage clinical development, the emphasis will likely shift toward establishing strategic partnerships with larger pharmaceutical entities to facilitate global distribution and market penetration. The ongoing commitment to refining its cyto-immunotherapy technology suggests a long-term strategy aimed at addressing unmet needs in the oncology market, potentially setting a new standard for targeted cancer care.
See full Engeneic company page
